新开河品牌怎么样 申请店铺

我要投票 新开河在人参行业中的票数:665 更新时间:2026-01-20
新开河是哪个国家的品牌?「新开河」是 康美药业股份有限公司 旗下著名品牌。该品牌发源于吉林省通化市,由创始人马董在1997年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力新开河品牌出海!将品牌入驻外推网,定制新开河品牌推广信息,可以显著提高新开河产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

新开河怎么样

成立于1997年,较早布局中医药全产业,以中药饮片为核心,以智慧药房为抓手,打造大健康+大平台+大数据+大服务体系


康美药业股份有限公司(600518)成立于1997年,于2001年在上交所上市。公司秉承“心怀苍生、大爱无疆”的核心价值观和“用爱感动世界、用心经营健康”的经营理念,在国家振兴中医药事业战略指引下,较早布局中医药全产业,以中药饮片为核心,以智慧药房为抓手,打造“大健康+大平台+大数据+大服务”体系,成为中医药全产业链服务型“智慧+”大健康产业上市企业。

康美药业上至药材种植、药材交易,下至生产开发、终端销售,已基本贯穿中医药产业链的上、中、下游产业,业务渗透中医药全产业链的各个关键环节,有效地整合全产业链资源。公司先后在全国各地投资建立140多家涵盖药材种植、中药材交易市场、现代物流中心和产业基地等业务的企业。

在全国建立了17个中药饮片和医药现代化生产基地,与超过2000家医疗机构、20万家药店建立了合作关系,年门诊总量达到2.5亿人次以上,投资管理康美医院、康美梅河口中心医院、康美通辽医院、康美开原市中心医院、康美通城人民医院、康美柳河中心医院等多家公立医院,在100多家公立医院开展医药物流延伸配送服务。

公司以国家中医药管理局信息化医疗服务平台试点单位为契机,把互联网深度布局全产业链中,以中药饮片为核心,以智慧药房为抓手,围绕“大健康+大平台+大数据+大服务”体系,以全产业链资源优势,积极探索中医药工业智能制造4.0,较早打造“智慧药房”模式。“智慧药房”模式上升为行业标准,为患者提供了“一站式”药事服务。截止2018年三季度,康美智慧药房累计处方量710万张,服务患者250万人,实现了“让信息多跑路,让群众少跑腿”。

康美药业丰富的医疗资源为公司以互联网思维、技术,改造和升级传统医疗健康产业,打造具有优良用户体验、覆盖全生命周期、一站式完整医疗服务闭环的移动健康管理大平台,奠定了坚实的基础。


Founded in 1997, Kangmei Pharmaceutical Co., Ltd. (600518) was founded in 1997 and listed on the Shanghai Stock Exchange in 2001. It has an early layout of the whole industry of traditional Chinese medicine, with herbal pieces as the core and smart pharmacies as the starting point to build a big health + big platform + big data + big service system. The company adheres to the core values of "caring for the world, loving the boundless" and the business philosophy of "moving the world with love and managing health with heart". Under the guidance of the national strategy of rejuvenating the cause of traditional Chinese medicine, the whole industry of traditional Chinese medicine is laid out earlier, with Chinese herbal pieces as the core and smart pharmacies as the starting point, and the system of "big health + big platform + big data + big service" is built to become the whole industry of traditional Chinese medicine Chain service-oriented "wisdom +" large health industry listed enterprises. Kangmei pharmaceutical industry has basically run through the upstream, midstream and downstream industries of TCM industry chain from the planting and trading of medicinal materials to the production and development and terminal sales. Its business penetrates all key links of the whole industry chain of TCM and effectively integrates the resources of the whole industry chain. The company has successively invested and established more than 140 enterprises covering medicine planting, Chinese medicine trading market, modern logistics center and industrial base. It has established 17 modern production bases of Chinese herbal pieces and medicine, established cooperative relations with more than 2000 medical institutions and 200000 pharmacies, with an annual outpatient volume of more than 250 million person times, invested and managed many hospitals, including Kangmei hospital, Kangmei Meihekou Central Hospital, Kangmei Tongliao hospital, Kangmei Kaiyuan Central Hospital, Kangmei Tongcheng people's Hospital and Kangmei Liuhe central hospital Public hospitals, in more than 100 public hospitals to carry out pharmaceutical logistics extended distribution services. Taking the opportunity of the pilot unit of the informatization medical service platform of the State Administration of traditional Chinese medicine, the company takes the Internet as an in-depth layout in the whole industry chain, with Chinese herbal pieces as the core, smart pharmacy as the starting point, around the "big health + big platform + big data + big service" system, and with the resource advantages of the whole industry chain, actively explores the intelligent manufacturing 4.0 of the traditional Chinese medicine industry, and builds the "smart pharmacy" model earlier Type. The mode of "smart pharmacy" has risen to the industry standard, providing patients with "one-stop" pharmaceutical services. As of the third quarter of 2018, Kangmei smart pharmacy has accumulated 7.1 million prescriptions, served 2.5 million patients, and realized "let more information run more, let the masses run less". Kangmei pharmaceutical's rich medical resources have laid a solid foundation for the company to transform and upgrade the traditional medical and health industry with internet thinking and technology, and to build a mobile health management platform with excellent user experience, covering the whole life cycle and one-stop complete medical service closed-loop.

本文链接: https://brand.waitui.com/f1e75a350.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

上交所就瑞茂通相关事项下发监管工作函

36氪获悉,上交所晚间发布关于瑞茂通供应链管理股份有限公司相关事项的监管工作函,涉及对象为上市公司、董事、高级管理人员、控股股东及实际控制人,处理事由为就公司信息披露事项明确监管要求。

2小时前

盈方微:股票将于1月20日复牌

36氪获悉,盈方微公告,公司股票将于2026年1月20日开市时起复牌。此前,公司因筹划发行股份及支付现金购买资产并募集配套资金的事项存在不确定性,自2026年1月6日起停牌。公司决定不再推进对时擎智能科技有限公司的股权收购,但将继续推进对上海肖克利信息科技股份有限公司及富士德中国有限公司的收购,并募集配套资金。相关审计和评估工作尚未完成,公司将在完成后再次召开董事会审议并依法定程序召集股东会。

2小时前

荣耀Magic 8 Pro Air发布

36氪获悉,荣耀正式发布荣耀Magic8 Pro Air,4999元起售。据介绍,该产品搭载天玑9500第三代3nm全大核旗舰芯片。

2小时前

*ST天微:公司股票可能被终止上市

36氪获悉,*ST天微公告,公司于2025年4月30日披露了《关于实施退市风险警示暨停牌的公告》,公司因2024年度实现归属于上市公司股东的扣除非经常性损益前后的净利润孰低为负值,且2024年度实现扣除与主营业务无关的业务收入后营业收入将低于人民币1亿元,根据有关规定,公司股票于2025年5月6日起被实施退市风险警示。若公司出现《股票上市规则》第12.4.10条规定的情形,公司股票可能被上海证券交易所终止上市。请广大投资者注意投资风险。

2小时前

TCL科技:董事长提名王成担任公司首席执行官(CEO)

36氪获悉,TCL科技公告,因经营管理需要,公司董事长李东生提名王成担任公司首席执行官(CEO),全面负责日常经营管理工作,李东生不再兼任。2026年1月19日,第八届董事会第十九次会议审议通过该议案,王成任期至公司第八届董事会任期截止日。王成现任公司首席运营官,持有公司股票268,220股,符合任职条件。

2小时前

本页详细列出关于新开河的品牌信息,含品牌所属公司介绍,新开河所处行业的品牌地位及优势。
咨询